Trial intelligence / Profile preview

Western medicine interventions in preclinical Alzheimer’s disease (971 vs rivastigmine vs placebo)

ChiCTR2100052254Phase 4Recruiting

Sponsor
Xuanwu Hospital
Start
Sep 2018
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial of rivastigmine in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (3 arms), sponsored by Xuanwu Hospital. Primary endpoint: AVLT score. Started Sep 2018; status: recruiting.

02

Drugs

rivastigmine
03

Conditions

Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)

Beyond the preview

Go deeper on ChiCTR2100052254.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100052254.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call